Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction.
Menghoum N. et al, (2025), Cardiovasc Diabetol, 24
Myocardial ischaemia following COVID-19: a cardiovascular magnetic resonance study.
Arnold JR. et al, (2025), Int J Cardiovasc Imaging, 41, 247 - 256
Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.
Tahir UA. et al, (2024), Circ Heart Fail, 17
Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency.
Piechnik SK. et al, (2024), Br J Haematol
Clinical Significance of Myocardial Injury in Patients Hospitalized for COVID-19: A Prospective, Multicenter, Cohort Study.
Shiwani H. et al, (2024), JACC Cardiovasc Imaging, 17, 1320 - 1331
Cardiovascular Magnetic Resonance Before Invasive Coronary Angiography in Suspected Non-ST-Segment Elevation Myocardial Infarction.
Shanmuganathan M. et al, (2024), JACC Cardiovasc Imaging, 17, 1044 - 1058
The association between adverse childhood experiences and adult cardiac function in the UK Biobank.
Quiroz JC. et al, (2024), Eur Heart J Imaging Methods Pract, 2
The Role of Coronary Blood Flow and Myocardial Edema in the Pathophysiology of Takotsubo Syndrome.
Couch LS. et al, (2024), JACC Cardiovasc Imaging, 17, 835 - 837
Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway.
Vera-Aviles M. et al, (2024), Eur Heart J
Automatic Plane Pose Estimation for Cardiac Left Ventricle Coverage Estimation via Deep Adversarial Regression Network
Zhang L. et al, (2024), IEEE Transactions on Artificial Intelligence, 5, 4738 - 4752
Concurrent Left Ventricular Myocardial Diffuse Fibrosis and Left Atrial Dysfunction Strongly Predict Incident Heart Failure.
Wong MYZ. et al, (2023), JACC Cardiovasc Imaging
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study.
C-MORE/PHOSP-COVID Collaborative Group None., (2023), Lancet Respir Med, 11, 1003 - 1019
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial.
Balligand J-L. et al, (2023), JAMA Cardiol, 8, 1031 - 1040